With a human papillomavirus (HPV) vaccine soon to become available for widespread use,
several studies have modelled the cost-effectiveness of vaccination. These pioneer studies …

Background: With promising efficacy results from randomized control trials of human
papillomavirus (HPV) vaccines and the availability of new screening paradigms …

Abstract Background The World Health Organization (WHO) recommends that the cost
effectiveness of introducing human papillomavirus (HPV) vaccination is considered before …

We describe a simplified model, based on the current economic and health effects of human
papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old …

Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted
and nine studies were identified in different countries. Due to the heterogeneity among these …

Background First generation bivalent and quadrivalent human papillomavirus (HPV)
vaccines have been introduced in most developed countries. A next generation nonavalent …

Objective To assess the cost effectiveness of including preadolescent boys in a routine
human papillomavirus (HPV) vaccination programme for preadolescent girls. Design Cost …

Background Human papillomavirus (HPV) is the most widespread sexually transmitted
infection worldwide. It causes several health consequences, in particular accounting for the …